Clinical trial
Everolimus Added to Long Acting Octreotide as a Volume Reducing Treatment of Polycystic Livers
NCT01157858 is registered in ClinicalTrials.gov with Radboud University Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Everolimus Added to Long Acting Octreotide as a Volume Reducing Treatment of Polycystic Livers
- Lead sponsor
- Radboud University Medical Center
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 30, 2010
- Completion date
- July 31, 2012
- Enrollment
- 44 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
polycystic liver disease